EQL Pharma AB (publ) (FRA:7JK)
Germany · Delayed Price · Currency is EUR 4.900
-0.005 (-0.10%)
At close: Nov 28, 2025
EQL Pharma AB Income Statement
Financials in millions SEK. Fiscal year is April - March.
Millions SEK. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 399.07 | 373.52 | 264.17 | 259.91 | 409.75 | 179.14 | Upgrade |
| 399.07 | 373.52 | 264.17 | 259.91 | 409.75 | 179.14 | Upgrade | |
Revenue Growth (YoY) | 26.14% | 41.39% | 1.64% | -36.57% | 128.73% | 148.70% | Upgrade |
Cost of Revenue | 236.26 | 217.56 | 149.12 | 144.06 | 314.02 | 128.14 | Upgrade |
Gross Profit | 162.81 | 155.95 | 115.05 | 115.85 | 95.73 | 51.01 | Upgrade |
Selling, General & Admin | 89.86 | 78.46 | 70.8 | 59.79 | 48.16 | 28.3 | Upgrade |
Research & Development | 12.45 | 11.26 | 12.09 | 15.14 | 9.13 | 11.7 | Upgrade |
Other Operating Expenses | -1.36 | -1.14 | -0.46 | -0.41 | -0.4 | -0.51 | Upgrade |
Operating Expenses | 100.95 | 88.58 | 82.43 | 74.51 | 56.9 | 39.48 | Upgrade |
Operating Income | 61.86 | 67.37 | 32.62 | 41.34 | 38.84 | 11.52 | Upgrade |
Interest Expense | -23.85 | -12.34 | -5.73 | -2.37 | -2.87 | -1.1 | Upgrade |
Interest & Investment Income | 0.01 | 0.01 | 0.2 | 0 | - | - | Upgrade |
Other Non Operating Income (Expenses) | -0.68 | -0.68 | -0 | - | 0 | - | Upgrade |
EBT Excluding Unusual Items | 37.34 | 54.36 | 27.08 | 38.97 | 35.97 | 10.42 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 1.53 | - | - | - | Upgrade |
Pretax Income | 37.34 | 54.36 | 28.6 | 38.97 | 35.97 | 10.42 | Upgrade |
Income Tax Expense | 7.73 | 11.23 | 5.9 | 8.05 | 4.42 | 0.06 | Upgrade |
Net Income | 29.61 | 43.12 | 22.71 | 30.92 | 31.55 | 10.37 | Upgrade |
Net Income to Common | 29.61 | 43.12 | 22.71 | 30.92 | 31.55 | 10.37 | Upgrade |
Net Income Growth | -5.01% | 89.93% | -26.57% | -1.99% | 204.32% | 282.97% | Upgrade |
Shares Outstanding (Basic) | 29 | 29 | 29 | 29 | 29 | 29 | Upgrade |
Shares Outstanding (Diluted) | 30 | 30 | 30 | 30 | 29 | 29 | Upgrade |
Shares Change (YoY) | 3.09% | 0.34% | 0.91% | 1.59% | - | -3.37% | Upgrade |
EPS (Basic) | 1.01 | 1.48 | 0.78 | 1.06 | 1.09 | 0.36 | Upgrade |
EPS (Diluted) | 0.98 | 1.44 | 0.76 | 1.04 | 1.09 | 0.36 | Upgrade |
EPS Growth | -7.66% | 89.47% | -26.92% | -4.19% | 204.32% | 296.33% | Upgrade |
Free Cash Flow | -19.19 | -30.78 | -12.36 | 27.16 | 41.2 | 59.64 | Upgrade |
Free Cash Flow Per Share | -0.63 | -1.03 | -0.41 | 0.92 | 1.42 | 2.05 | Upgrade |
Gross Margin | 40.80% | 41.75% | 43.55% | 44.57% | 23.36% | 28.47% | Upgrade |
Operating Margin | 15.50% | 18.04% | 12.35% | 15.90% | 9.48% | 6.43% | Upgrade |
Profit Margin | 7.42% | 11.54% | 8.60% | 11.90% | 7.70% | 5.79% | Upgrade |
Free Cash Flow Margin | -4.81% | -8.24% | -4.68% | 10.45% | 10.05% | 33.29% | Upgrade |
EBITDA | 71.23 | 75.68 | 38.81 | 47.37 | 40.54 | 16.57 | Upgrade |
EBITDA Margin | 17.85% | 20.26% | 14.69% | 18.23% | 9.89% | 9.25% | Upgrade |
D&A For EBITDA | 9.37 | 8.31 | 6.19 | 6.03 | 1.7 | 5.05 | Upgrade |
EBIT | 61.86 | 67.37 | 32.62 | 41.34 | 38.84 | 11.52 | Upgrade |
EBIT Margin | 15.50% | 18.04% | 12.35% | 15.90% | 9.48% | 6.43% | Upgrade |
Effective Tax Rate | 20.70% | 20.66% | 20.62% | 20.65% | 12.28% | 0.53% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.